The U.S. Food and Drug Administration (FDA) on Tuesday approved a new, simplified monthly dosing schedule for Johnson & Johnson’s (NYSE:JNJ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj).

When administered in combination with oral Lazcluze (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consistent outcomes with the previously approved bi-weekly subcutaneous (SC) dosing schedule.

The milestone builds upon the recent FDA approval of Rybrevant Faspro, which transformed administration time from hours to minutes and offers a fivefold reduction in administration-related reactions (ARRs) when compared to intravenous (IV) ...